Professor Robin Choudhury

Professor Robin Choudhury is a consultant interventional cardiologist (honorary) at the Oxford Heart Centre and Oxford University Hospitals NHS Trust (since 2005) and Professor of Cardiovascular Medicine at Oxford University. He qualified in medicine at the University of Oxford with postgraduate training in London at Royal Brompton, Hammersmith and St Mary’s hospitals and in New York at Mount Sinai Medical Centre.

His NHS clinical practice is in interventional and general cardiology. He has particular expertise in optimising cardiovascular risk factors.

He is a former President of the Royal Society of Medicine Section on Lipids, Metabolism and Vascular Risk. He has led numerous clinic trials and studies in this area including the use of canakinumab, a novel interleukin-1β neutralising antibody in patients with diabetes and vascular disease. He is UK Chief Investigator for the ZEUS trial of the anti-interleukin-6 agent, ziltivekimab. Prof. Robin Choudhury leads the Novo Nordisk Foundation funded MeRIAD programme on metabolic influences in cardiovascular disease, an international collaboration between Oxford and Copenhagen Universities and the Karolinska Institute.

He has published over 200 articles on aspects of cardiovascular disease. He is a Section Editor (Clinical Cardiology) for the Journal of the American College of Cardiology, the world’s leading journal on cardiovascular disease.

His approach is one of clear explanation that addresses both the medical problem and any attendant anxieties. He seeks to empower patients to make evidence-based and informed decisions.